Relief in Hours, Not Weeks
Many patients experience meaningful improvement within hours to days — a critical advantage for those in acute distress or who have waited months for other treatments to work.
The first FDA-approved nasal spray for treatment-resistant depression and major depressive disorder with acute suicidal ideation — administered safely in our Portland clinic.
Schedule a Consultation
Spravato (esketamine) is an FDA-approved nasal spray that targets NMDA receptors — a completely different mechanism from traditional antidepressants. Approved in 2019 for treatment-resistant depression and in 2020 for MDD with acute suicidal ideation.
Where oral antidepressants can take 4–8 weeks to show effect, many patients notice significant improvement within hours to days of their first Spravato session.
Compare With TMS Therapy
A breakthrough option when standard antidepressants haven't been enough.
Many patients experience meaningful improvement within hours to days — a critical advantage for those in acute distress or who have waited months for other treatments to work.
Spravato follows an established induction and maintenance schedule with rigorous FDA oversight, giving patients and providers confidence in the treatment pathway.
Administered in our certified REMS facility with at least two hours of post-dose monitoring by clinical staff. You cannot receive Spravato at a pharmacy.
Spravato is covered by most commercial insurance and Medicare Part B when FDA criteria are met. We handle all prior authorization paperwork.
Esketamine rapidly increases synaptic glutamate and promotes neuroplasticity — helping the brain form new, healthier connections that support lasting mood improvement.
Spravato is always prescribed alongside an oral antidepressant. Your psychiatrist manages both medications and coordinates with your therapist.
Each visit lasts approximately 2.5 hours, including self-administration of the nasal spray and a mandatory two-hour monitoring period. You must arrange a driver — you cannot drive after a session.
Spravato is FDA-approved for adults who meet specific criteria and are currently taking an oral antidepressant.
Our psychiatrists conduct a thorough evaluation to confirm Spravato is safe and appropriate before your first session.
Confirm diagnosis, review medication history, and determine if Spravato criteria are met.
We verify benefits, obtain prior authorization, and enroll you in the REMS program.
Twice-weekly nasal spray administration with 2-hour monitored recovery in our clinic.
Transition to weekly then biweekly sessions. Ongoing psychiatry and therapy continue.